

Hematological and Pathological Studies on the Effect of Warfarin in Male Albino Rats.

A Thesis

*Submitted for the Degree of Master of Science as a partial Fulfilment
for the Requirements of the Master of Science*

In Physiology / Zoology,
Faculty of Science

By

Mohamed Said Mohamed Hassan Abu Elkheir
(B.Sc. Zoology / Chemistry, 2006)

Supervised By

Prof. Dr. Nefissa Hussein Meky

*Professor of Physiology
Zoology Department, Faculty of Science
Ain Shams University*

Prof. Dr. Essam Mohammed Ibraheem

Deputy Director of Animal Health Research Institute

Dr. Hoda Gamal El-Deen Hegazy

*Assistant Professor of Physiology
Zoology Department, Faculty of Science
Ain Shams University*

**Faculty of Science
Ain Shams University**

2016

بسم الله الرحمن الرحيم





﴿وَقُلْ رَبِّ زِدْنِي عِلْمًا﴾

سورة طه الآية رقم ١١٤

A decorative border with a repeating floral and scrollwork pattern in blue, green, and gold, framing the central text.

Dedication

I dedicate this work

-  *To my father*
-  *To my mother and family*
-  *To my wonderful wife for her
support and encouragement*
-  *To my lovely daughter Hoda*

Acknowledgement

First of all, all gratitude is due to **God** almighty for blessing this work, until it has reached its end, as a part of his generous help, throughout my life.

Really I can hardly find the words to express my gratitude to **Prof. Dr. Nefissa Hussein Meky**, Professor of physiology, Zoology Department, Faculty of Science, for her supervision, continuous help, encouragement throughout this work and tremendous effort she has done in the meticulous revision of the whole work. It is a great honor to work under her guidance and supervision.

Really I can hardly find the words to express my gratitude to **Prof. Dr. Essam Mohammed Ibraheem**, Deputy Director of Animal Health Research Institute, for his continuous directions and meticulous revision throughout the whole work. I really appreciate his patience and support.

At last to the one who shared by great part **Dr. Hoda Gamal El-din Hegazy**, for the great role she played in my life that helped me at college, she gave me the first hope and she makes my dream so close.

Contents

| | Page |
|---|------|
| List of abbreviations..... | i |
| List of tables | ii |
| List of Figures | iii |
| List of photomicrographs | |
| Abstract | |
| Chapter 1 | |
| Introduction | 1 |
| Aim of the work | 4 |
| Chapter 2 | |
| 2. Review of literature..... | 5 |
| 2.1.Warfarin mechanism of action | 7 |
| 2.2.Toxicity of warfarin | 10 |
| 2.2.1.Effect on human | 10 |
| 2.3.Teratogenicity | 11 |
| 2.4.Effects on non target species..... | 12 |
| 2.5.Clinical effects of warfarin | 13 |
| 2.6.Factors influence warfarin dose response | 14 |
| 2.6.1.Age | 14 |
| 2.6.2.Body mass index | 15 |
| 2.7.Effect of warfarin in different organ | 16 |
| 2.7.1.Liver diseases | 16 |
| 2.7.2.Renal diseases | 18 |
| 2.7.3.Thyroid diseases | 19 |
| 2.7.4.Surgery and blood loss | 20 |
| 2.8.Monitoring anticoagulation intensity | 21 |
| 2.9.The antithrombotic effect of warfarin..... | 23 |
| 2.10.Nonhemorrhagic adverse effects of warfarin..... | 24 |
| 2.11.Clinical applications of oral anticoagulant therapy .. | 24 |

Contents (Cont.)

| | Page |
|---|-------------|
| 2.12.Natural anticoagulant | 25 |
| 2.12.1.Protein C..... | 25 |
| 2.12.2.Protein S | 29 |
| 2.13.Overview on oxidative stress | 30 |
| 2.13.1.Impact of oxidative stress on kidney tissue | 32 |
| 2.13.2.Sources of reactive oxygen species..... | 33 |
| 2.13.2.1.Endogenous sources | 33 |
| 2.13.2.2.Exogenous source of free radicals | 34 |
| 2.13.3.Markers of oxidative stress | 35 |
| 2.13.3.1.Lipid peroxidation..... | 35 |
| 2.13.3.2.Protein oxidation | 35 |
| 2.13.3.3.Nucleic acid oxidation | 36 |
| 2.14.Overview on antioxidant and health maintenance | 36 |
| 2.14.1.Endogenous antioxidants | 39 |
| 2.14.1.1. Superoxide dismutase | 39 |
| 2.14.1.2.Catalase | 40 |
| 2.14.1.3.Glutathione | 40 |
| 2.14.1.3.1.Cellular glutathione..... | 42 |
| 2.14.1.3.2. Mitochondrial glutathione..... | 43 |
| 2.14.1.3.3.Transport of glutathione | 43 |
| 2.14.1.3.3.1.Liver | 43 |
| 2.14.2.Exogenous antioxidant | 44 |
| Chapter 3 | |
| 3.Materils and methods | 46 |
| 3.1.Material | 46 |
| 3.1.1. Experimental animals | 46 |
| 3.1.2. Warfarin | 46 |
| 3.2.Methods | 47 |
| 3.2.1.Experimental design | 47 |
| 3.2.2.Sampling..... | 47 |
| 3.2.2.1.Blood samples | 47 |

Contents (Cont.)

| | Page |
|---|-------------|
| 3.2.2.2.Tissue samples | 48 |
| 3.3. Assays..... | 48 |
| 3.3.1. Estimation of biochemical parameters..... | 48 |
| 3.3.1.1. Estimation of serum triglycerides | 48 |
| 3.3.1.2. Estimation of serum cholesterol | 50 |
| 3.3.1.3. Estimation of serum high density lipoprotein- cholesterol content | 51 |
| 3.3.1.4. Estimation of serum low density lipoprotein cholesterol | 52 |
| 3.3.1.5. Estimation of aspartate aminotransferase . | 53 |
| 3.3.1.6. Estimation of creatine kinase | 54 |
| 3.3.1.7. Estimation of lactate dehydrogenase | 55 |
| 3.3.2.Determination of heamatological parameters | 56 |
| 3.3.2.1. Determination of prothrombin time | 56 |
| 3.3.2.2. Determination of partial thromboplastin time | 57 |
| 3.3.2.3.Determination of protein C | 58 |
| 3.3.2.4. Determination of protein S | 59 |
| 3.3.2.5.Determination of erythrocyte osmotic fragility | 61 |
| 3.3.2.6. Blood viscosity measurements..... | 62 |
| 3.3.3.Estimation of oxidative stress markers | 63 |
| 3.3.3.1.Determination of total antioxidant status level | 63 |
| 3.3.3.2.Measurement of total oxidant status level | 64 |
| 3.3.3.3.Determination of total nitric oxide | 65 |
| 3.3.3.4. Reduced / oxidized glutathione | 66 |
| 3.3.4.Histological investigation | 68 |
| 3.3.5.Statistical analysis | 68 |
| Chapter 4 | |
| Results | 69 |

Contents (Cont.)

Page

Chapter 5

| | |
|----------------------|-----|
| Discussion | 99 |
| Summary | 114 |
| References | 119 |
| Arabic summary | -- |
| Arabic abstract..... | -- |

List of Abbreviations

| | |
|-------------------------------|---------------------------------|
| ALT | Alanine amino transferase |
| AMI | Acute myocardial infarction |
| APC | Activated protein C |
| AST | Aspartate amino transferase |
| BMI | Body Mass Index |
| CE | Cholesterol esteras |
| CGS | Centimeter- gram- second |
| CHOD | Cholesterol oxidase |
| CK | Creatine Kinase |
| CKD | Chronic kidney disease |
| CNS | Central Nervous System |
| CYp1A1 | Cytochrome p 1A1 |
| CYp1A2 | Cytochrome p1A2 |
| CYP2C9 | Cytochrome p2C9 |
| CYp3A4 | Cytochrome p3A4 |
| CYP450 | Cytochrome p450 |
| EPCR | Endothelial protein C receptor |
| GGCX | γ -glutamyle carboxylase |
| GK | Glycerol kinase |
| GPO | Glycerol phosphate oxidase |
| GSH | Glutathione |
| GSSG | Oxidized glutathione |
| H ₂ O ₂ | Hydrogen peroxide |
| HDL-C | High density lipoprotein |
| HOCL- | Hypochloric acid |
| INR | International normalized ratio |
| ISI | International Sensitivity Index |

List of Abbreviations

| | |
|-------------------|--|
| LDL-C | Low density lipoprotein |
| M pa.s | Milli- pascal- second |
| MDH | Malate dehydrogenase |
| MKS | Meter – kilogram- second |
| NEM | N-ethylmaleimide |
| NO● | Nitric oxide |
| O ₂ ●- | Superoxide |
| O ₃ | Ozone |
| OD | Optical density |
| ONOO- | Peroxynitrite |
| PC | Protein C |
| PCI | Activated protein C inhibitor |
| POD | Peroxidase |
| PS | Protein S |
| PT | Prothrombin time |
| PTT | Partial thromboplastin time |
| RO● | Alkoxy |
| ROO● | Peroxy |
| ROOH | Peroxide |
| ROS | Reactive oxgen species |
| RS● | Thiyl |
| SOD | Superoxide dismutase |
| TAS | Total anti oxidant status |
| TNO | Total nitric oxide |
| TOS | Total oxidant status |
| VKOR | Vitamin K epoxide reductase |
| VKORC1 | Vitamin K epoxide reductase complex subunit 1 |
| VLDL-C | Very low density lipoprotein |
| XO | Xanthine oxidase |

List of Tables

| <i>Table</i> | <i>Title</i> | <i>Page</i> |
|--------------|--|-------------|
| 1 | Effect of warfarin (0.03 mg/100 g b.wt.) on plasma prothrombin time (sec), partial thromboplastin time (sec), plasma protein C (%) and protein S (%) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 71 |
| 2 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum cholesterol (mg /dl), triglycerides (mg/dl), high density lipoprotein (mg/dl), and low density lipoprotein (mg/dl) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 75 |
| 3 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum aspartate aminotransferase (u/l), alanine aminotransferase (u/l), creatine kinase (u/l), lactate dehydrogenase (u/l) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 79 |
| 4 | Effect of warfarin (0.03 mg/100 g b.wt.) on blood viscosity (mPa.s) and red blood cell osmotic fragility (%) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 82 |
| 5 | Effect of warfarin (0.03 mg/100 g b.wt.) on reduced / oxidized glutathione (n mol/ g tissue) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 85 |
| 6 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum levels of total oxidant status ($\mu\text{mol H}_2\text{O}_2\text{Equiv./L}$), total antioxidant status (m molTrolox Equiv./L) and total nitric oxide ($\mu\text{mol/L}$) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 89 |

List of Figures

| <i>Fig.</i> | <i>Title</i> | <i>Page</i> |
|--------------------|---|--------------------|
| 1 | Effect of warfarin (0.03 mg/100 g b.wt.) on plasma prothrombin time (sec) and partial thromboplastin time (sec) in male albino rats after 2 weeks of treatment (group 1) and 4 weeks of treatment (group 2). | 72 |
| 2 | Effect of warfarin (0.03 mg/100 g b.wt.) on plasma protein C (%) and protein S (%) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 72 |
| 3 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum cholesterol (mg/dl), triglycerides (mg/dl) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 76 |
| 4 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum high density lipoprotein (mg/dl) and low density lipoprotein (mg/dl) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 76 |
| 5 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum aspartate aminotransferase (u/l), alanine aminotransferase (u/l) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 80 |
| 6 | Effect of warfarin (0.03 mg/100 g b.wt.) on lactate dehydrogenase (u/l) and creatine kinase (u/l) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 80 |

List of Figures (Cont.)

| <i>Fig.</i> | <i>Title</i> | <i>Page</i> |
|--------------------|---|--------------------|
| 7 | Effect of warfarin (0.03 mg/100 g b.wt.) on blood viscosity (mPa.s) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 83 |
| 8 | Effect of warfarin (0.03 mg/100 g b.wt.) on red blood cell osmotic fragility (%) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 83 |
| 9 | Effect of warfarin (0.03 mg/100 g b.wt.) on reduced / oxidized glutathione (n mol/g tissue) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 86 |
| 10 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum total oxidant status ($\mu\text{mol H}_2\text{O}_2\text{Equiv./L}$), total antioxidant status (mmol Trolox Equiv./L) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 90 |
| 11 | Effect of warfarin (0.03 mg/100 g b.wt.) on serum total nitric oxide ($\mu\text{mol/L}$) in male albino rats after 2 weeks of treated (group 1) and 4 weeks of treated (group 2). | 90 |

List of Photomicrographs

| Photomicrographs | <i>Title</i> | <i>Page</i> |
|-------------------------|---|--------------------|
| 1 | Photomicrograph of section of normal rat's liver. H and E., x 400. | 93 |
| 2 | Photomicrograph of section of rat's liver received 0.06 mg warfarin / 100 g b.wt for 10 successive days. H and E., x 400. | 93 |
| 3 | Photomicrograph of section of rat's liver received 0.03 mg warfarin / 100 g b.wt for two successive weeks. H and E., x 200. | 94 |
| 4 | Photomicrograph of section of rat's liver received 0.03 mg warfarin / 100 g b.wt for four successive weeks. H and E, x 200. | 94 |
| 5 | Photomicrograph of section of normal rat's kidney. H and E, x 200. | 95 |
| 6 | Photomicrograph of section of rat's kidney received 0.06 mg warfarin / 100 g b.wt for 10 successive days. H and E., x 200. | 95 |
| 7 | Photomicrograph of section of rat's kidney received 0.03 mg warfarin / 100 g b.wt for two successive weeks. H and E., x 400. | 96 |
| 8 | Photomicrograph of section of rat's kidney received 0.03 mg warfarin / 100 g b.wt for four successive weeks, H and E., x 400. | 96 |

List of Photomicrograph (Cont.)

| Photomicrographs | <i>Title</i> | <i>Page</i> |
|-------------------------|---|--------------------|
| 9 | Photomicrograph of section of normal rat's spleen. H and E., x 200. | 97 |
| 10 | Photomicrograph of section of rat's spleen received 0.06 mg warfarin / 100 g b.wt for 10 successive days.H and E., x 200. | 97 |
| | Photomicrograph of section of rat's spleen received 0.03 ml of warfarin for two successive weeks. H and E., x 200. | 98 |
| 11 | Photomicrograph of section of rat's spleen received 0.03 ml of warfarin for four successive weeks days.H and E., x 200. | 98 |